Metraipolis › archive › dc_3249e63b3e86

A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide — Europe PMC PMID:42959026

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42959026
DOI
10.3389/fphar.2026.1945154
License (as archived)
solo-consultazione
Archived
2026-10-31T17:14:54.354Z
SHA-256 of the archived text
30b1e455f7f5add02327b8a4e36d5d178d19ead5bddbc1f1e7e9278d8fd547cf
Stable URL of this page
https://metraipolis.com/documento/dc_3249e63b3e86

How to cite

A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide — Europe PMC PMID:42959026 — Europe PMC (en), https://europepmc.org/article/MED/42959026 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3249e63b3e86 (Metraipolis archive dc_3249e63b3e86, sha256 30b1e455f7f5add02327b8a4e36d5d178d19ead5bddbc1f1e7e9278d8fd547cf)
BibTeX
@misc{dc3249e63b3e86,
  title = {A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide — Europe PMC PMID:42959026},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42959026},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3249e63b3e86; sha256 30b1e455f7f5add02327b8a4e36d5d178d19ead5bddbc1f1e7e9278d8fd547cf},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42959026. Agents can read the archived copy with the MCP tool read_document.